Literature DB >> 3982951

Food and a sustained release theophylline tablet on chronic dosing: bioavailability, peak-trough and trough-trough differences.

M Lagas, J H Jonkman.   

Abstract

The bioavailability of theophylline and the serum concentration fluctuations after administration of a sustained release tablet (Theograd 250 mg, one tablet twice daily) were studied in the steady state in six volunteers. On postprandial administration of the 250 mg tablets the bioavailability was 89 +/- 16%. Good sustained release properties were obtained provided that the tablets were taken after a meal; Cmax was 7.9 +/- 2.0 mg X 1(-1), tmax was 5.3 +/- 1.6 h, the peak-trough difference was 2.3 +/- 0.6 mg X 1(-1) and the serum concentration fluctuation was accounted for 42.8 +/- 11.2%. It was shown that on postprandial administration the mean serum concentration-time profile could be successfully calculated by means of multiple dose projection from single dose data. However, when the a.m. dose was given on an empty stomach and the p.m. dose 3 h after a meal, it appeared not to be possible to use the single diurnal dose data for calculation of the steady state serum concentration-time profile: the experimentally observed a.m. trough levels were significantly higher than the p.m. trough values and also the observed mean serum concentration was significantly higher than the calculated level. The possible causes for this discrepancy are extensively discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3982951     DOI: 10.1007/bf01962863

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  15 in total

1.  Comparison of standard- and sustained-release theophylline tablets in patients with chronic obstructive pulmonary disease.

Authors:  J Dasta; J M Mirtallo; M Altman
Journal:  Am J Hosp Pharm       Date:  1979-05

2.  Rational intravenous doses of theophylline.

Authors:  P A Mitenko; R I Ogilvie
Journal:  N Engl J Med       Date:  1973-09-20       Impact factor: 91.245

3.  Comparison at steady state of sustained-release theophylline tablets and capsules.

Authors:  C J Newth; A F Isles
Journal:  J Asthma       Date:  1982       Impact factor: 2.515

4.  Investigation of diurnal changes in the disposition of theophylline.

Authors:  D R Taylor; D Duffin; C D Kinney; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1983-10       Impact factor: 4.335

5.  Sustained-release theophylline for childhood asthma: evidence for circadian variation of theophylline pharmacokinetics.

Authors:  P H Scott; E Tabachnik; S MacLeod; J Correia; C Newth; H Levison
Journal:  J Pediatr       Date:  1981-09       Impact factor: 4.406

6.  Theophylline bioavailability following oral administration of six sustained-release preparations.

Authors:  D L Spangler; D D Kalof; F L Bloom; H J Wittig
Journal:  Ann Allergy       Date:  1978-01

7.  Efficacy of a 12-hour sustained-release preparation in maintaining therapeutic serum theophylline levels in asthmatic children.

Authors:  H W Kelly; S Murphy
Journal:  Pediatrics       Date:  1980-07       Impact factor: 7.124

8.  Chronopharmacokinetics of theophylline after sustained release and intravenous administration to adults.

Authors:  J H Jonkman; W J van der Boon; L P Balant; R Schoenmaker; A Holtkamp
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

9.  Evaluation of the absorption from some commercial sustained-release theophylline products.

Authors:  R A Upton; J F Thiercelin; T W Guentert; L Sansom; J R Powell; P E Coates; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1980-04

Review 10.  Experience with theophylline for the management of chronic asthma.

Authors:  M Weinberger; L Hendeles
Journal:  Eur J Respir Dis Suppl       Date:  1980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.